Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMO | Q99835 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13679575 | 0.88 | MAPT (0.73) | MAPTLMNAGAATP53MEN1 | |
| SCHEMBL15424127 | 0.85 | MAPT (0.68) | MAPTTP53MEN1HTTKMT2A | |
| SCHEMBL15424154 | 0.84 | MAPT (0.49) | MAPTLMNAGAATP53MEN1 | |
| SCHEMBL15424153 | 0.84 | MAPT (0.59) | MAPTLMNAGAATP53MEN1 | |
| SCHEMBL15424156 | 0.84 | MAPT (0.72) | MAPTLMNAGAATP53MEN1 | |
| SCHEMBL13679552 | 0.84 | MAPT (0.69) | MAPTTP53MEN1HTTKMT2A | |
| SCHEMBL15424157 | 0.83 | MAPT (0.63) | MAPTLMNAGAATP53MEN1 | |
| SCHEMBL14615282 | 0.83 | MAPT (0.68) | MAPTLMNAGAAMEN1HTT | |
| SCHEMBL19685458 | 0.83 | MAPT (0.53) | MAPTLMNAGAATP53MEN1 | |
| SCHEMBL20145731 | 0.82 | MAPT (0.63) | MAPTLMNATP53MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708299-B2 | Hedgehog antagonists having zinc binding moieties | GENENTECH, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GENETECH, INC. (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GLI1, SHH, HDAC1 | MAPT 3245/4885LMNA 4754/4885GAA 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.